REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:41 UTC
-
Experimental combo aims to outsmart Hard-to-Treat lymphomas
Disease control Recruiting nowThis early-phase study tests whether combining two drugs—nivolumab (an immunotherapy that helps the immune system attack cancer) and ASTX727 (a pill that makes chemotherapy more effective)—is safe and can shrink tumors in people with B-cell lymphoma that has returned or stopped r…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:30 UTC
-
Double attack: vaccine boosts CAR T-Cells against tough lymphoma
Disease control Recruiting nowThis early-phase study tests whether combining a patient's own modified immune cells (CAR T-cells) with a special vaccine is safe and possible for people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The CAR T-cells are designed to find and kil…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 10:30 UTC
-
New immune cell combo takes on tough lymphoma
Disease control Recruiting nowThis study tests whether a new treatment combining specially designed immune cells (ONC-PluReceptor NK cells) with two antibody drugs (epcoritamab and tafasitamab) can control B-cell Non-Hodgkin lymphoma that has returned or not responded to prior therapies. About 30 adults aged …
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 10:25 UTC
-
New combo therapy targets tough lymphoma cases
Disease control Recruiting nowThis study tests a drug called loncastuximab tesirine combined with other anti-cancer drugs in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goals are to check safety and find the best dose. About 200 adults aged 18 and older …
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Smart bomb for lymphoma: targeted drug trial seeks to shrink tumors
Disease control Recruiting nowThis phase 2 trial tests whether loncastuximab tesirine can shrink tumors in 20 adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug is a targeted therapy that attaches to a protein on cancer cells and delivers a chemotherapy agent directl…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 15, 2026 11:53 UTC